VIVO - FDA requests additional information on Meridian Revogene COVID test
The FDA late Feb. 12 requested that Meridian Bioscience (VIVO) provide additional information for an Emergency Use Authorization application for its SARS-CoV-2 molecular diagnostic test based on the Revogene platform.The company says it plans to send a response to the agency later today.Meridian will hold shipments of the test kits as it works with the FDA.Meridian shares are unchanged premarket and closed down 0.2% to $29.82 on Feb. 12.
For further details see:
FDA requests additional information on Meridian Revogene COVID test